With 14.04 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.38 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.4265 whereas the lowest price it dropped to was $0.3664. The 52-week range on EQ shows that it touched its highest point at $1.50 and its lowest point at $0.34 during that stretch. It currently has a 1-year price target of $1.00. Beta for the stock currently stands at 1.94.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of EQ was up-trending over the past week, with a rise of 6.59%, but this was up by 1.15% over a month. Three-month performance dropped to -50.45% while six-month performance fell -46.97%. The stock lost -45.36% in the past year, while it has lost -48.34% so far this year. A look at the trailing 12-month EPS for EQ yields -0.39 with Next year EPS estimates of -1.09. For the next quarter, that number is -0.18. This implies an EPS growth rate of -269.57% for this year and -28.24% for next year.
Float and Shares Shorts:
At present, 35.72 million EQ shares are outstanding with a float of 17.58 million shares on hand for trading. On 2025-05-30, short shares totaled 88654.0, which was 25.0 higher than short shares on 1745971200. In addition to Mr. Daniel Mark Bradbury as the firm’s Executive Chairman, Mr. Bruce D. Steel C.F.A. serves as its Co-Founder, President, CEO & Director.
Institutional Ownership:
Through their ownership of 0.19139 of EQ’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, EQ reported revenue of $0.0 and operating income of -$8870000.0. The EBITDA in the recently reported quarter was -$8837000.0 and diluted EPS was -$0.24.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for EQ since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With EQ analysts setting a high price target of 1.0 and a low target of 1.0, the average target price over the next 12 months is 1.0. Based on these targets, EQ could surge 156.41% to reach the target high and rise by 156.41% to reach the target low. Reaching the average price target will result in a growth of 156.41% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $11.625 being high and -$6.375 being low. For EQ, this leads to a yearly average estimate of -$0.375.
